NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
2.550
-0.090 (-3.41%)
Mar 26, 2026, 4:00 PM EDT - Market closed
NovaBridge Biosciences Employees
NovaBridge Biosciences had 32 employees as of December 31, 2024. The number of employees decreased by 188 or -85.45% compared to the previous year.
Employees
32
Change (1Y)
-188
Growth (1Y)
-85.45%
Revenue / Employee
n/a
Profits / Employee
-$822,688
Market Cap
293.99M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 32 | -188 | -85.45% |
| Dec 31, 2023 | 220 | -158 | -41.80% |
| Dec 31, 2021 | 378 | 150 | 65.79% |
| Dec 31, 2020 | 228 | 43 | 23.24% |
| Dec 31, 2019 | 185 | 51 | 38.06% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AC Immune | 172 |
| Cabaletta Bio | 151 |
| Foghorn Therapeutics | 106 |
| Armata Pharmaceuticals | 60 |
| Crescent Biopharma | 44 |
| Surrozen | 41 |
| Avalo Therapeutics | 23 |
| Immix Biopharma | 21 |
NBP News
- 11 days ago - NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer - GlobeNewsWire
- 17 days ago - NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript - Seeking Alpha
- 17 days ago - Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease - Benzinga
- 18 days ago - NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study - GlobeNewsWire
- 23 days ago - NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 - GlobeNewsWire
- 25 days ago - NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform - GlobeNewsWire
- 5 weeks ago - NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer - GlobeNewsWire